The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
Status:
Not yet recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
To evaluate the short-term and longer-term safety, tolerability, and effectiveness of
neoadjuvant and adjuvant Pembrolizumab on top of standard therapy (Stupp protocol) in
patients with Glioblastoma Multiforme (GBM).
Randomized comparison of safety, tolerability, and clinical efficacy of (1) neoadjuvant and
adjuvant Pembrolizumab (on top of Stupp protocol, n=12 patients), (2) neoadjuvant
Pembrolizumab (on top of Stupp protocol, n=12 patients), and (3) standard of care (Stupp
protocol only, n=12 patients). Immuno-PET examination will be performed before and after
surgery in all patients.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Silesia
Collaborator:
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice